This Plain Language Summary of Publication article (PLSP) from Future Oncology, evaluated treatment options for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received prior treatment. Patients were divided into three groups: acalabrutinib alone, acalabrutinib with the monoclonal antibody obinutuzumab, or standard chemoimmunotherapy (chlorambucil plus a monoclonal antibody). The study compared these approaches to assess their effectiveness.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia’ and was published in the Leukemia.

Visit Nature using the link to read the original article.